title: Strategies for management of prostate cancer-related bone pain.
abstract: Prostate cancer is one of the most common malignancies and a leading cause of cancer-related death in men worldwide. In the majority of cases, prostate cancer metastases to the skeleton, in which case cancer-related bone pain becomes a major cause of morbidity. Androgen ablation is the treatment of choice for securing regression of skeletal metastases in the majority of cases. Intermittent androgen ablation is an attractive alternative, aimed at minimising adverse effects of hormone deprivation but also potentially delaying hormone-refractoriness. The development of hormone-refractoriness is heralded by a significant increase in morbidity largely because of escalating bone pain caused by the progression of the metastatic process. Skillful use of analgesics is initially successful but eventually fails to control symptoms. Localised metastases are best treated with local radiotherapy that is rapidly effective. Over the last few years, it has become clear that therapeutic modalities using bone-seeking radionuclides or bisphosphonates have been effective in the palliation of prostate cancer-related bone pain, although not affecting survival. The main limiting factor with the use of radionuclides is bone marrow suppression, also a feature of the very late stages of prostate cancer. Bisphosphonates do not carry this disadvantage. Results of large double-blind, placebo-controlled studies should be awaited, however, before advocating the widespread use of these agents in the management of patients with prostate cancer and skeletal metastases.
authors.affiliation: Department of Urology, Leiden University Medical Center, Leiden, The Netherlands. r.c.m.pelger@lumc.nl
authors.forename: R C
authors.initials: RC
authors.lastname: Pelger
authors.forename: V
authors.initials: V
authors.lastname: Soerdjbalie-Maikoe
authors.forename: N A
authors.initials: NA
authors.lastname: Hamdy
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D004002:Clodronic Acid / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010146:Pain / Q000209:etiology / Q000532:radiotherapy; D059408:Pain Management; D011471:Prostatic Neoplasms / Q000150:complications / Q000532:radiotherapy / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D011868:Radioisotopes; D004002:Clodronic Acid